Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

wasp venom cancer

News and Trends 8 Sep 2015

Wasp venom kills Cancer cells

Side effects of cancer treatments are almost as feared as the disease itself. But what if we could selectively destroy cancer cells without harming normal cells? Wasp venom might hold the secret to this largely awaited solution, as researchers from São Paulo State University and University of Leeds unraveled the mechanism of its cancer-targeting toxin. […]

September 8, 2015 - 2 minutesmins - By Lourdes Riquelme

shutterstock 121346014

News and Trends 7 Sep 2015

Biotech Crowdfunding in Europe: Trendy but only 0.2% of total VC money raised since 2010

Figures for the amount raised for EU biotechs since 2010 suggest although crowdfunding is considered a massive springboard for small startups, in reality, it has a much more limited range of use. Perhaps we have too high an ambition for crowdfunding as a financial tool for biotech? Crowdfunding is in the general media so often […]

September 7, 2015 - 2 minutesmins - By Dani Bancroft

Immatics

News and Trends 7 Sep 2015

A Slice of Europe: MD Anderson looks to invest in EU Immuno-Oncology

MD Anderson is expanding its Immatics sharehold to spawn new Houston-based subsidiary Immatics US through investing into a $60M (€54M) pot. Also partnering up with French CAR-T pioneers Cellectis, and collaborating with German Merck, MD Anderson is seemingly wanting to immerse itself in the European immuno-oncology field. As a shareholder in the German cancer immunotherapy […]

September 7, 2015 - 3 minutesmins - By Dani Bancroft

IP One Cisbio

News and Trends 7 Sep 2015

A reliable technology to develop the next generation of GPCR targeted medicines

You must have heard of GPCRs, or more specifically G protein-coupled receptors. Doesn’t ring a bell? You know, it’s this large protein family of receptors that sense molecules outside the cell and trigger an inside signal. A technology called IP-One could give a large advantage to scientists working on GPCR-targeted drugs. We had the opportunity to […]

September 7, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 5 Sep 2015

Genzyme pays another $32.5M for cheating on one of its product’s supposed applications

Genzyme’s $22.28M (€20M) penalty wasn’t enough for the US Department of Justice to resolve its criminal marketing of Seprafilm. Sanofi’s biotech subsidiary will therefore have to pay another $32.5M (€29,2M) to avoid further legal implications. Criminal charges caught Cambridge-based Genzyme by promoting its tape-like Seprafilm for wrong allegations between 2005 and 2010, up until one year […]

September 5, 2015 - 2 minutesmins - By Philip Hemme

gdgegreg

News and Trends 5 Sep 2015

Top 5 Things you need to know from outside the EU this week: (Truvada, Nanoclews, CRISPR-Cas9)

Oh hey there…another Top 5 topics you need to know from outside Europe this week. Enjoy and if you have time, give us some feedback! BREAKTHROUGH TABLET PREVENTS HIV INFECTION IN UP TO 92% OF HIGH RISK CASES HIV Tablet ‘Truvada‘: San Francisco health Insurance firm Kaiser Permanente published a study on Tuesday showed out of the […]

September 5, 2015 - 3 minutesmins - By Dani Bancroft

ADVERTISEMENT

simris large1

News and Trends 4 Sep 2015

Sweden, Vegan and GMO-Free? Check out Simris Alg for your Omega-3

By running an innovative microalgae farm in Hammenhög, Sweden, Simris Alg produces a vegan and GMO-free Omega-3 fatty acid alternative to oily fish derivatives for industry. This Swedish start-up is winning all kinds of awards for their almost too-good-to-be-true approach to dietary Omega-3 oils. The Swedish entrepreneur Fredrika Gullfot (CEO) has improved upon a sustainable alternative to producing Omega-3 oils through a pioneering […]

September 4, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 4 Sep 2015

CAR-T therapy first clinical proof: Patient lives cancer-free 5 years on

A pioneering CAR-T cell therapy study from Novartis and the University of Pennsylvania demonstrates the impressive potential of the next-generation therapy. Five years after the start of the study, three patients have achieved complete remission and remain cancer-free. Here it is, the proof that the hype about CAR-T cell therapy was no hollow promise. Penn’s […]

September 4, 2015 - 4 minutesmins - By Philip Hemme

weizmann

News and Trends 4 Sep 2015

Gut bacteria growth time can cause disease?

A method of profiling bacterial growth time in the gut’s microbiome has been shown to be a rudimentary diagnostic tool for IBS and diabetes type II. A research team came together from the labs of Dr Elinav and Professor Segal to investigate at the Weizmann Institute of Science, Israel. The millions of bacteria living within our […]

September 4, 2015 - 3 minutesmins - By Dani Bancroft

Large Image

News and Trends 3 Sep 2015

Adaptimmune Clinical Trials full-steam ahead with GSK investment!

Adaptimmune has had exciting results regarding the ongoing battle with Synovial Sarcoma. GSK looks to further invest in the expansion of the clinical trial to include two further cohorts. Adaptimmune, with a research base in Oxford (UK) and clinical base in Philadelphia (US), has overcome a milestone in their first cohort for clinical stage I/II T-cell therapy. They […]

September 3, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 3 Sep 2015

Malin has a new Captain aboard to guide and boost its Investments in British Biotechs

Irish life science investment company Malin reshuffles its executive board and gives its former director, Kelly Martin, the new CEO position. The Ex-Elan chief will further push investments in British biotechs. Kelly Martin takes over as CEO of Malin and will balance opportunities and risk in the company’s investments, as well as running day to day […]

September 3, 2015 - 2 minutesmins - By Philip Hemme

Marck 1 Large 2

News and Trends 3 Sep 2015

Startups receive €25K investment as part of Merck’s brand new Accelerator Program

Merck – the German healthcare company has announced the 3 start-ups it plans to adopt into its in-house accelerator program. Two of the participants focus on e-health, while the third, Sulfotools, has developed a cleaner and cheaper method of solid-phase protein synthesis (SPPS). Merck has awarded these start-ups with a €25K investment as a ‘silent’ investor as […]

September 3, 2015 - 4 minutesmins - By Dani Bancroft

ADVERTISEMENT